山梨医科大学雑誌　第5巻1号　025-034(1990)

A Proposal of Effctive Immunochemotherapy Using Recombinant Interleukin 2 and Adriamycin, and Its Theoretical Background

Yasuyoshi YAMAMOTO, Hidehiko IIZUKA, Masayuki YAMAMOTO, Kachio TASAKA,
and Katsuhiko SUGAHARA

Abstract: We performed immunochemotherapy using a continuous infusion of recombinant interleukin 2 (IL2) and intermittent one-shot-injections of Adriamycin (ADR) administered directly to the hepatic artery in 6 cases of advanced hepatocellular carcinoma (HCC). Although the observation periods were short, the tumors reduced in size; most notably, a massive tumor in the right lobe disappeared in one case. After reviewing the 6 patients with HCC, we demonstrated a possible cause of ADR as a kind of immuno-modifier. In an in vitro study, the susceptibility of subpopulations of lymphocytes to ADR was variable with the suppressor T cell being more susceptible to ADR compared to the helper T cell. In HCC patients, the ratio of the suppressor T cells to the helper T cells (suppressor/helper ratio) was significantly higher than that of the healthy controls. Thus, following the administration of the optimal dose of ADR, specific decrease in the suppressor T cell and increase in the helper T cell in response to ADR can be obtained for the recovery of the suppressor/helper ratio. Moreover, ADR-treated lymphocytes of HCC patients exhibited constant killer activity in the presence of IL2. Although the optimal dose of ADR for clinical use may be within a very narrow range, ADR combined with IL2 following tumor mass-reduction treatments may restore the immunity of advanced HCC patients and prolong their survival.

Key words: Immunochemotherapy, Recombinant interleukin 2, Adriamycin, Liver cancer, Surface marker




本文は、編集委員会の意向によりインターネットには公開しておりません。図書館等でご覧ください。

Texts are not availavle on Internet.



目次・Contentsに戻る